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IS CISATRACURIUM COST EFFECTIVE FOR NEUROMUSCULAR BLOCKADE IN THE ICU? A MARKOV COMPUTER SIMULATION STUDY
. The objective of this study was to examine the incremental cost-effectiveness ratio (ICER) of cisatracurium versus using a traditional steroid based agent-vecuronium. METHODS: We designed a Markov ICER computer model. The base case involved a 55-year-old man admitted to the ICU for ARDS and then paralyzed for 3.5 days. Patients were modeled to be in one of the following health states: ICU-intubated, ICUextubated, hospital ward, long-term care, home, or death. Patient progression was divided into 3.5 day cycles over six months. One trial found the average recovery after cisatracurium to be one hour versus 6 hours with vecuronium. Approximately 27% of ICU patients paralyzed for 3.5 days would be expected to develop MYOPATHY within 7 days. However, it is not evident that cisatracurium reduces this incidence. RESULTS: Our modeling predicted the total cost for an ARDS patient to be $58,629. At 6 months: mortality = 43%, patients discharged home = 32%, in-hospital = 8%, and long term care facility = 17%. Using average wholesale prices, cisatracurium costs $599 for 3.5 days, versus $332 for vecuronium. The modeling suggests that cisatracurium is cost-effective (the ICER is < $35,000/QALY) if intubation time is reduced by 7%, or if ICU extubated time is reduced by 1.8%, or if the time the patient is in the ward is reduced by 2.3%. CONCLUSIONS: Incremental costs for cisatracurium are a very small portion of the total cost of care for ARDS patients. If cisatracurium use leads to very small reductions in ICU time, or ward length, it becomes a cost-effective intervention. 
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ECONOMIC OUTCOMES OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH INHALED CORTICOSTEROIDS AND LONG-ACTING b-AGONISTS IN A HEALTH MAINTENANCE ORGANIZATION
OBJECTIVES:
There is growing recognition of the public health challenge posed by treating persons with chronic obstructive pulmonary disease (COPD). Although treatment options are limited, observational studies have shown that long-acting beta agonists (LABA) and/or inhaled corticosteroids (ICS) may prolong survival. We investigated the cost-effectiveness of competing strategies for treating COPD. METHODS: Subject-level cost and
